Thursday 16 October, 2025
Introduction: Advancements in facilitating access to antiretroviral therapy (ARV) are evident, with 29.8 million out of 39 million HIV positive…
Read moreAbstracts
Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite
Thursday 16 October, 2025
Introduction: Clopidogrel, an antiplatelet agent, exhibits complex pharmacokinetics. It is rapidly absorbed after oral administration and extensively metabolized in the…
Read morePrediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia
Thursday 16 October, 2025
Objectives. Sepsis is major cause of mortality in neonates. Blood cultures are often negative, antibiotic (AB) dosing cannot be always…
Read moreRivaroxaban Population Pharmacokinetics Modeling in Iranian Patients
Thursday 16 October, 2025
Backgrounds: Recently, rivaroxaban has been used for the approved indications in Iranian patients and has been developed as a favored…
Read morePIPETapps: a Compilation of R Shiny Apps for Clinical Pharmacology and Pharmacometrics using Cloud Computing Tools
Thursday 16 October, 2025
Objectives: Modeling and simulation tools for pharmacokinetics (PK) and pharmacodynamics (PD) analysis usually require advanced abilities and knowledge of users…
Read moreApplying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC)
Thursday 16 October, 2025
Introduction: KRAS mutation occur in 30% of all human cancers [1], however, this target is known to be undruggable until…
Read moreRituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity
Thursday 16 October, 2025
Objectives: Addition of rituximab to the standard-of-care chemotherapy cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) leads to significant improvement in the long-term…
Read moreDetermination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is the leading cause of death from a single infectious agent worldwide1. The fact that the lengthy 6-month…
Read moreImplementation of the standard concentration – QTc study using MonolixSuite applications on the example of Dofetilide.
Thursday 16 October, 2025
Objectives: QT interval is the period when ventricles start to contract to when they finish. But when this period becomes…
Read moreA library of parent-metabolite models for the MonolixSuite
Thursday 16 October, 2025
Objectives: For most drugs, a total or part of a dose undergoes a biotransformation before elimination from the human body. It…
Read more